Lipoglycopeptides, Outpatient Parenteral Antibiotic Therapy, and the Infectious Disease Doctor—Moving Forward

2018 ◽  
Vol 26 (3) ◽  
pp. 121-122 ◽  
Author(s):  
Donald M. Poretz
2016 ◽  
Vol 3 (4) ◽  
Author(s):  
Russell M. Petrak ◽  
Nathan C. Skorodin ◽  
Robert M. Fliegelman ◽  
David W. Hines ◽  
Vishnu V. Chundi ◽  
...  

Abstract Background.  Outpatient parenteral antibiotic therapy (OPAT) is a safe and effective modality for treating serious infections. This study was undertaken to define the value of OPAT in a multicentered infectious disease (ID) private practice setting. Methods.  Over a period of 32 months, 6120 patients were treated using 19 outpatient ID offices in 6 states. Analysis included patient demographics, indications of OPAT, diagnoses, therapeutic agent, duration of therapy, and site of therapy initiation. Outcomes were stratified by therapeutic success, clinical relapse, therapeutic complications, and hospitalizations after initiating therapy. Statistical analysis included an ordinal logistic regression analysis. Results.  Forty-three percent of patients initiated therapy in an outpatient office, and 57% began therapy in a hospital. Most common diagnoses treated were bone and joint (32.2%), abscesses (18.8%), cellulitis (18.5%), and urinary tract infection (10.8%). Ninety-four percent of patients were successfully treated, and only 3% were hospitalized after beginning therapy. Most common cause of treatment failure was a relapse of primary infection (60%), progression of primary infection (21%), and therapeutic complication (19%). Conclusions.  An ID-supervised OPAT program is safe, efficient, and clinically effective. By maximizing the delivery of outpatient care, OPAT provides a tangible value to hospitals, payers, and patients. This program is a distinctive competency available to ID physicians who offer this service to patients.


2020 ◽  
Vol 8 ◽  
Author(s):  
Aryono Hendarto ◽  
Nina Dwi Putri ◽  
Dita Rizkya Yunita ◽  
Mariam Efendi ◽  
Ari Prayitno ◽  
...  

2021 ◽  
Vol 11 (2) ◽  
pp. 153-159
Author(s):  
Elizabeth Townsley ◽  
Jessica Gillon ◽  
Natalia Jimenez-Truque ◽  
Sophie Katz ◽  
Kathryn Garguilo ◽  
...  

2007 ◽  
Vol 46 (3) ◽  
pp. 247-251 ◽  
Author(s):  
Sabiha Hussain ◽  
Margarita M. Gomez ◽  
Peter Wludyka ◽  
Thomas Chiu ◽  
Mobeen H. Rathore

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Raagini Jawa ◽  
Hallie Rozansky ◽  
Dylan Clemens ◽  
Maura Fagan ◽  
Alexander Y. Walley

2020 ◽  
Vol 65 (1) ◽  
pp. e02099-20
Author(s):  
Laura Herrera-Hidalgo ◽  
Arístides de Alarcón ◽  
Luis Eduardo López-Cortes ◽  
Rafael Luque-Márquez ◽  
Luis Fernando López-Cortes ◽  
...  

ABSTRACTCeftriaxone administered as once-daily high-dose short infusion combined with ampicillin has been proposed for the treatment of Enterococcus faecalis infective endocarditis in outpatient parenteral antibiotic therapy programs (OPAT). This combination requires synergistic activity, but the attainment of ceftriaxone synergic concentration (Cs) with the regimen proposed for OPAT has not been studied. This phase II pharmacokinetic study enrolled healthy adult volunteers who underwent two sequential treatment phases. During phase A, volunteers received 2 g of ceftriaxone each 12 h during 24 h followed by a 7-day wash-out. Then the participants received phase B, which consisted of a single dose of 4 g of ceftriaxone. Throughout both phases, each volunteer underwent intensive pharmacokinetic (PK) sampling over 24 h. Ceftriaxone total and unbound concentrations were measured. Twelve participants were enrolled and completed both phases. Mean ceftriaxone total and free concentrations 24 h after the administration of 2 g each 12 h were 86.44 ± 25.90 mg/liter and 3.59 ± 1.35 mg/liter, respectively, and after the 4-g single dose were 34.60 ± 11.16 mg/liter and 1.40 ± 0.62 mg/liter, respectively. Only 3 (25%) patients in phase A maintained unbound plasma concentrations superior to the suggested Cs = 5 mg/liter during 24 h, and none (0%) in phase B. No grade 3 to 4 adverse events or laboratory abnormalities were observed. Ceftriaxone optimal exposure combined with ampicillin to achieve maximal synergistic activity against E. faecalis required for the treatment of infective endocarditis remains unknown. However, the administration of a single daily dose of 4 g of ceftriaxone implies a reduction in the time of exposure to the proposed Cs. (This study has been registered in the European Union Drug Regulating Authorities Clinical Trials [EudraCT] database under identifier 2017-003127-29.)


Sign in / Sign up

Export Citation Format

Share Document